Uniqure Stock Price, News & Analysis

uniQure (NASDAQ: QURE), a leading gene therapy company, will release its second quarter 2025 financial results before market open on Tuesday, July 29, 2025. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results.

The earnings call will be accessible via webcast through uniQure's website under the Events & Presentations section, with a replay available for 90 days. Phone participants must pre-register online to receive dial-in details and are advised to join 15 minutes before the start time.

uniQure (NASDAQ: QURE) has appointed Kylie O'Keefe as Chief Customer and Strategy Officer, effective June 6, 2025. O'Keefe will lead the global commercialization strategy for AMT-130, the company's investigational gene therapy for Huntington's disease, with a potential U.S. launch in 2026. She brings extensive experience in rare diseases and gene therapy from her previous role as Chief Commercial Officer at PTC Therapeutics, where she managed global commercial operations across 50+ countries and led launches including Upstaza for AADC deficiency. At uniQure, O'Keefe will oversee commercial functions and medical affairs, leveraging her expertise in reimbursement strategies, payer engagement, and health economic assessments. The appointment strengthens uniQure's leadership team as they prepare to transition into a commercial-stage biotechnology company with AMT-130, which could become the first disease-modifying treatment for Huntington's disease.

uniQure (NASDAQ: QURE) has announced significant progress in its regulatory pathway for AMT-130, its gene therapy treatment for Huntington's disease. Following FDA meetings, the company has aligned on key components for a Biologics License Application (BLA) planned for Q1 2026 under an Accelerated Approval pathway. The FDA has agreed that the composite Unified Huntington's Disease Rating Scale (cUHDRS) can serve as a registrational endpoint, with primary efficacy analysis comparing 3-year changes in high-dose AMT-130 patients against external controls from ENROLL-HD database. The FDA also approved CMC requirements, allowing validation using experience from HEMGENIX process plus additional GMP batches. Key upcoming milestones include submitting updated Statistical Analysis Plan in Q2 2025, presenting Phase I/II topline data in Q3 2025, conducting Process Performance Qualification run, and holding pre-BLA meeting in Q4 2025.

uniQure has presented promising early results from the first participant in its Phase I/IIa GenTLE clinical trial of AMT-260, a gene therapy candidate for refractory Mesial Temporal Lobe Epilepsy (MTLE). The patient, who previously experienced an average of seven seizures monthly, showed a remarkable 92% reduction in seizure frequency over five months post-treatment, with no seizures reported in the last 60 days and no serious adverse events. AMT-260 is a one-time gene therapy designed to suppress the GRIK2 gene and GluK2 expression, which are believed to trigger seizures. The ongoing trial will evaluate two dose cohorts of six patients each across 12 U.S. sites, with additional sites planned by end of 2025.

uniQure (NASDAQ: QURE) reported Q1 2025 financial results and key developments. The company's AMT-130 for Huntington's disease received FDA Breakthrough Therapy designation, with initial safety data showing good tolerability. The company held FDA meetings to advance BLA preparations, with a regulatory update expected in Q2 2025. Financial highlights include cash position of $409.0 million as of March 31, 2025, expected to fund operations into H2 2027. Q1 revenues were $1.6 million, with a net loss of $43.6 million ($0.82 per share). The company completed a public offering raising $80.5 million. Pipeline progress includes AMT-260 for epilepsy, AMT-191 for Fabry disease, and AMT-162 for ALS, with various data presentations expected throughout 2025.

uniQure (NASDAQ: QURE) has announced it will report its first quarter 2025 financial results on Friday, May 9, 2025, before market open. The company will host its inaugural quarterly earnings conference call at 8:30 a.m. ET on the same day. This initiative to begin regular earnings calls comes as uniQure advances its pipeline and AMT-130 toward a BLA submission and potential commercialization, aiming to enhance engagement with the investment community.

The event will be accessible via webcast through uniQure's website, with a 90-day replay available afterward. Phone participants must pre-register through an online form to receive dial-in details and are advised to join 15 minutes before the start time.

uniQure (NASDAQ: QURE) has received FDA Breakthrough Therapy designation for AMT-130, its gene therapy treatment for Huntington's disease, a rare inherited neurodegenerative disorder with no current disease-modifying therapies.

The designation is based on promising interim data from Phase I/II trials showing dose-dependent slowing of disease progression. The company presented 24-month data in July 2024, demonstrating meaningful disease progression slowdown based on cUHDRS scores compared to natural history.

AMT-130 has already received Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, and Fast Track designations. The treatment has been administered to 45 patients to date, with additional regulatory guidance on the Biologics License Application expected in Q2 2025.

uniQure (NASDAQ: QURE) reported its 2024 financial results and company progress. Key highlights include FDA alignment on Accelerated Approval pathway for AMT-130 in Huntington's disease and completion of patient enrollment in its third cohort Phase I/II study. The company initiated dosing in Phase I/II studies for multiple programs including AMT-260 for epilepsy, AMT-191 for Fabry disease, and AMT-162 for SOD1-ALS.

Financial position shows cash and equivalents of $367.5 million as of December 31, 2024, plus $80.7 million from recent financing, expected to fund operations into second half of 2027. Revenue increased to $27.1 million in 2024 from $15.8 million in 2023. The company reported a net loss of $239.6 million ($4.92 per share) compared to $308.5 million ($6.47 per share) in 2023.

CSL Behring announced four-year results from the pivotal HOPE-B study of HEMGENIX, their gene therapy for hemophilia B. The data demonstrates sustained efficacy and safety through four years post-treatment. Key findings include:

- 94% of patients remained free of continuous factor IX prophylaxis
- Mean factor IX activity levels maintained at 37% through four years
- Approximately 90% reduction in mean adjusted annualized bleeding rate from lead-in to year four
- Joint bleeds reduced from 2.34 to 0.09 mean ABR

The Phase III HOPE-B trial involved 54 adult male participants with severe or moderately severe hemophilia B. No serious adverse events related to HEMGENIX were reported, with 96% of treatment-related adverse events occurring in the first six months. HEMGENIX, approved by FDA in 2022, is the first gene therapy for hemophilia B that can treat patients with and without AAV5 neutralizing antibodies.